Suven Life Sciences Limited (NSE:SUVEN)
India · Delayed Price · Currency is INR 265.99
-3.53 (-1.31%)
May 22, 2026, 3:29 PM IST
Suven Life Sciences Revenue
In the fiscal year ending March 31, 2026, Suven Life Sciences had annual revenue of 210.45M INR with 216.19% growth. Suven Life Sciences had revenue of 82.98M in the quarter ending March 31, 2026, with 465.64% growth.
Revenue
210.45M
Revenue Growth
+216.19%
P/S Ratio
333.33
Revenue / Employee
1.52M
Employees
138
Market Cap
70.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 210.45M | 143.89M | 216.19% |
| Mar 31, 2025 | 66.56M | -50.37M | -43.08% |
| Mar 31, 2024 | 116.93M | -19.02M | -13.99% |
| Mar 31, 2023 | 135.95M | 16.44M | 13.76% |
| Mar 31, 2022 | 119.51M | -21.23M | -15.08% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alembic Pharmaceuticals | 73.45B |
| Strides Pharma Science | 48.59B |
| Akums Drugs and Pharmaceuticals | 43.59B |
| Alivus Life Sciences | 25.52B |
| Cohance Lifesciences | 23.03B |
| Sun Pharma Advanced Research Company | 18.90B |
| Aarti Pharmalabs | 18.01B |
| Innova Captab | 16.30B |
Suven Life Sciences News
- 6 days ago - Suven Life Sciences shares rally over 17% today; Details here - Business Upturn
- 3 months ago - Pharma sector stocks today, Feb 4: Suven Life Sciences jumps 9%, Aarti Drugs falls 6%, Shilpa Medicare up 2.80%, Mankind Pharma down 2.92% - Business Upturn
- 5 months ago - Suven Life Sciences achieves 100% enrollment for Phase-2b Trial of Ropanicant for major depressive disorder - Business Upturn
- 1 year ago - Suven Life Sciences shares surge over 8% after clinical trial update - Business Upturn
- 1 year ago - Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107 - Business Upturn
- 1 year ago - Suven Life Sciences reports positive Phase-2a results for Ropanicant in treating Major Depressive Disorder - Business Upturn
- 1 year ago - Suven Life Sciences announces FDA acceptance of Investigational New Drug - Business Upturn